Alzheimer’s is the most expensive disease in the United States, and pharmaceutical companies are racing to find viable treatments for this devastating disease, which currently affects more than 5.3 million Americans and their loved ones. Wall Street is placing bets on who will win the race to treat Alzheimer’s, and India Globalization Capital (NYSE MKT: IGC) is one promising candidate with a compelling patent-pending treatment protocol. An excerpt from an article further discussing this reads: “IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics includes treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease. IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.”
To view the full article, visit http://cnw.fm/T4ldh
About India Globalization Capital
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us.
More from CannabisNewsBreaks
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
[email protected]
